Xoma | XOMA - Frais De Vente Et D'Administration





Frais De Vente Et D'Administration Changement Date
AbbVie USD 3.89B 325M 2025-12
Agenus USD 10.56M 13.04M 2025-12
Agios Pharmaceuticals USD 42.97M 1.7M 2025-12
Ardelyx USD 75.92M 7.69M 2025-12
aTyr Pharma USD 82.26M 77.46M 2025-12
BioMarin Pharmaceutical USD 322.21M 98.79M 2025-12
Celldex Therapeutics USD 7.84M 1.21M 2025-12
Curis USD 4.79M 100K 2024-06
Eli Lilly USD 3.13B 391.3M 2025-12
Emergent BioSolutions USD 182.8M 82.3M 2023-06
Incyte USD 390.41M 61.33M 2025-12
MacroGenics USD 7.94M 1.96M 2025-12
Novartis USD 3.44B 128M 2025-12
Novartis USD 3.44B 132M 2025-12
Pfizer USD 4.08B 894M 2025-12
Prothena USD 7.65M 5.59M 2025-12
Regeneron Pharmaceuticals USD 775M 117.2M 2025-12
Xoma USD 11M 2.54M 2024-06